Remogliflozin etabonate

Remogliflozin etabonate
Clinical data
Routes of; administration	By mouth
ATC code	none;
Legal status
Legal status	Investigational;
Pharmacokinetic data
Metabolism	Remoglifozin is metabolized primarily by cytochrome P450 (CYP) 3A4 and to a lesser extent by CYP2C19 to GSK 279782 (the active metabolite) and GSK 333081 before being glucuronidated to generate inactive glucuronide conjugates.
Identifiers
	IUPAC name 5-Methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside;
CAS Number	442201-24-3 ;
ChemSpider	8047110 ;
UNII	TR0QT6QSUL;
KEGG	D10055 ;
ChEMBL	ChEMBL494323 ;
CompTox Dashboard (EPA)	DTXSID50963191 ;
Chemical and physical data
Formula	C26H38N2O9
Molar mass	522.595 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OC1C(COC(=O)OCC)OC(C(O)C1O)Oc(nn(C(C)C)c2C)c2Cc3ccc(cc3)OC(C)C;
	InChI InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1 ; Key:UAOCLDQAQNNEAX-ABMICEGHSA-N ;
	(what is this?) (verify)

Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by BHV Pharma, a wholly owned subsidiary of North Carolina, US-based Avolynt, and Glenmark Pharmaceuticals through a collaboration with BHV. In 2002, GlaxoSmithKline (GSK) received a license to use it. From 2002 to 2009, GSK carried out a significant clinical development program for the treatment of type-2 diabetes mellitus in various nations across the world and obesity in the UK. Remogliflozin etabonate's pharmacokinetics, pharmacodynamics, and clinical dose regimens were characterized in 18 Phase I and 2 Phase II investigations. Due to financial concerns, GSK stopped working on remogliflozin and sergliflozin, two further SGLT2 inhibitors that were licensed to the company, in 2009. Remogliflozin was commercially launched first in India by Glenmark in May 2019.

Clinical data

Routes of administration	By mouth
ATC code	none
Legal status
Legal status	Investigational
Pharmacokinetic data
Metabolism	Remoglifozin is metabolized primarily by cytochrome P450 (CYP) 3A4 and to a lesser extent by CYP2C19 to GSK 279782 (the active metabolite) and GSK 333081 before being glucuronidated to generate inactive glucuronide conjugates.
Identifiers
IUPAC name 5-Methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside
CAS Number	442201-24-3^Y
ChemSpider	8047110^N
UNII	TR0QT6QSUL
KEGG	D10055^N
ChEMBL	ChEMBL494323^N
CompTox Dashboard (EPA)	DTXSID50963191
Chemical and physical data
Formula	C₂₆H₃₈N₂O₉
Molar mass	522.595 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES OC1C(COC(=O)OCC)OC(C(O)C1O)Oc(nn(C(C)C)c2C)c2Cc3ccc(cc3)OC(C)C
InChI InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1^N Key:UAOCLDQAQNNEAX-ABMICEGHSA-N^N
^NY (what is this?) (verify)